Galectin-3 has been suggested as a pro-inflammatory mediator in animal arthritis and rheumatoid arthritis (RA). We aimed to study the serum level of galectin-3 in patients with newly diagnosed RA and associations with disease profile, Magnetic resonance imaging (MRI) findings and seromarkers of synovial matrix inflammation. One hundred and sixty DMARD na€ ıve patients newly diagnosed with RA were included (CIMESTRA study). Clinical, serological and imaging data were recorded before treatment and at 6 weeks, 3 and 12 months. Galectin-3 and hyaluronan (HYA) were measured by ELISA (R&D and Corgenix, USA), and the N-terminal propeptide of type III collagen (PIIINP) by radioimmunoassay (Orion Diagnostica, Finland). One hundred and nineteen, 87 and 60 blood donors served as controls for galectin-3, HYA and PIIINP, respectively. Baseline galectin-3 was significantly elevated in anti-CCP positive (4.2 lg/l IQR [3.6;6.1]) patients as compared with anti-CCP negatives (4.0 lg/l [2.6;4.9], P = 0.05) and controls (3.8 lg/l [3.0;4.8], P < 0.01). During treatment, galectin-3 remained elevated, but increased transiently with peak values at 6 weeks. Galectin-3 correlated with baseline smoking, anti-CCP, and with MRI erosion score after 1 year of follow-up. HYA and PIIINP were elevated (P < 0.001) irrespective of anti-CCP status and correlated positively with synovitis assessed clinically and by MRI. HYA and PIIINP did not correlate with galectin-3. These observations indicate that HYA and PIIINP mainly reflect expansive synovitis proliferation while galectin-3 is more closely linked to autoimmunity, smoking and joint destructive processes.
Introduction
Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease characterized by polyarthritis, which frequently causes joint destruction and may disseminate to extra-articular sites [1] . Research based on clinical databases and biobanking has demonstrated that clinical RA is frequently antedated by occurrence of autoantibodies, which are important predictors of structural damage progression [2] . Of particular note, persistent subclinical synovitis and erosive progression have been demonstrated in many RA patients despite clinical remission [3, 4] .Galectin-3, a 26kD beta-galactoside-binding protein, is a multifunctional protein, which is expressed in a variety of cell types, including macrophages, monocytes and dendritic cells [5] . Galectin-3 is located within cells and on cell surfaces [6] and is supposed to serve innate immune defence purposes, for example by enhancing cytokine production, modulating cell adhesion, and by inhibiting or promoting apoptosis [7] . Furthermore, these properties as well as stimulation of cancer cell invasion and angiogenesis are considered to be implicated in cancer metastasis [8] . Ohshima et al. [9] were first to report that galectin-3 and its binding protein are overexpressed in RA synovitis, particularly at the pannus-cartilage junction. In their small series of long-standing RA patients, these authors found that galectin-3 was increased in synovial fluid and serum compared with osteoarthritis patients and healthy controls. In addition, our group has recently reported that galectin-3 is higher in pre-RA than in early, undifferentiated arthritis of non-RA origin [10] . Additional experimental research has provided further evidence for a role of galectin-3 in the RA disease pathway. Thus, in a study on mice with arthritis by Forsman et al., bone erosions were significantly less in GAL-3À/À mice as compared with wild-type animals [11] . Likewise, Filer and co-workers showed that galectin-3 enhances mononuclear chemokine expression in rheumatoid arthritis synovial fibroblasts (RASFs), while not in normal skin fibroblasts [12] . Considering that persistent synovitis in RA leads to enhanced synovial fibrogenesis which is an important determinant for longterm disability, it is of particular interest that galectin-3 has been reported to mediate profibrotic functions in many tissues, presumably by enhancing fibroblast proliferation and extracellular matrix expression [13] . Interestingly, a positive correlation has been demonstrated between the N-terminal propeptide of type III collagen (PIIINP), a marker of type III collagen synthesis and galectin-3 in patients with chronic heart failure. Increased circulating levels of PIIINP and other soft connective tissue constituents have previously been reported in active rheumatoid arthritis [14] [15] [16] .We therefore hypothesized that galectin-3 in newly diagnosed RA may be associated with structural joint lesions and that galectin-3 in serum correlates with serum levels of early fibrosis markers including hyaluronan (HYA), reflecting the inflammatory oedema, and PIIINP, a molecular marker of the provisional reticulin network preceding development of mature collagen type I fibrosis.
Materials and methods
All study participants consented to participate in writing. The trial was carried out in accordance with the Declaration of Helsinki and was approved by the local ethics committee (M1959-98). The study also fulfilled the International Conference on Harmonisation 1996 revised Guidelines for Good Clinical Practice in the European Community (NCT00209859). Study population and treatment outline. This study was conducted on patients who participated in the CIMESTRA (Cyclosporine, Methotrexate, Steroid in RA) trial [17] . Briefly, the study comprised 160 patients with newly diagnosed, untreated RA (< 6 months disease duration), according to the 1987 American College of Rheumatology criteria [18] , who had two or more swollen joints at inclusion. Core clinical and imaging data have previously been reported [17, [19] [20] [21] [22] .
At baseline, the patients were 18-75 years old, diseasemodifying antirheumatic drugs (DMARD) na€ ıve and had not received treatment with glucocorticoids in the preceding 4 weeks. Mild analgesics was allowed on demand. Further exclusion criteria were previous use of DMARDs, treatment with glucocorticoids in the preceding 4 weeks, past or present malignancy, diastolic blood pressure of > 90 mmHg despite treatment with antihypertensive agents, kidney disease, infection with parvovirus B19, hepatitis B, hepatitis C, or human immunodeficiency virus and any condition contraindicated for the study medication.
The patients were randomized into two treatment arms, receiving either methotrexate (MTX) 7.5 mg weekly plus cyclosporine 2.5 mg/kg/day (combination therapy) or MTX plus placebo-cyclosporine (monotherapy). Swollen joints were injected with betamethasone (7 mg/mlmaximum 4 joints or 4 ml per visit) at baseline, week 2, 4, 6, 8 and every 4 weeks thereafter up to week 52. If swollen joints were present from week 8, the methotrexate dosage was increased by 2.5 mg/week every 4 weeks to a maximum of 20 mg/week. Likewise, the cyclosporine/ placebo-cyclosporine dosage was increased by 0.5 mg/day every 4 weeks to a maximum of 4 mg/kg body weight starting at week 28. All patients received folic acid as well as calcium and vitamin D supplementation. Joint evaluation and injections were performed by a blinded and trained assessor.
Disease activity and disability measures were evaluated on a regular basis including Disease Activity Score in 28 joints (DAS28-CRP), a 40-joint count, serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), Health Assessment Questionnaire (HAQ) score and Visual Analogue Scales (VAS (0-100 mm) -pain assessment, physician and global assessment).
Control subjects. One hundred and nineteen self-reportedly healthy male and female blood donors aged 20-70 years, evenly distributed according to decades and gender and without current medication besides over the counter drugs, served as reference population for galectin-3. For PIIINP and HYA, healthy female and male blood donors were recruited from the blood bank at Odense University Hospital as control subjects. Sixty blood donors aged 20-78 served as controls for PIIINP and 87 blood donors aged 23-64 for HYA.
Laboratory analyses. Serum from patients was obtained from routinely drawn non-fasting blood samples collected between 08 a.m. and 2 p.m. Prior to centrifugation at 2000 g for 10 min, the blood samples were allowed to clot at room temperature. Following centrifugation, the serum was stored at À80°C until analysis.
Galectin-3 was measured at baseline, and after 6 weeks, 3 and 12 months using ELISA (R&D systems) according to the instructions by the manufacturer. Briefly, standards (100 ng of recombinant human galectin-3), controls and patient samples were dispensed into microplates coated with a mouse monoclonal antibody against galectin-3.
Upon incubation and washing, polyclonal antibody against galectin-3 conjugated to horse-radish peroxidase was added. All samples were run in duplicate. The intra-and interassay coefficients of variation in our laboratory amounted to 3.9% and 14.9%, respectively. The reference interval for serum galectin-3 was estimated to be 1.7-7.5 lg/l (2.5 and 97.5 percentiles) with a 95% confidence interval of 0.8;1.9 and 6.5;10.0 for lower and upper limit, respectively. Due to inadequate sample volume, three patients were excluded. One outlier in the control study population was excluded.
The N-terminal propeptide of type III collagen (PIIINP) was measured at baseline using a radioimmunoassay (Orion Diagnostica, Finland) according to the instructions by the manufacturer. The assay is based on a reference human PIIINP antigen and polyclonal antibodies raised in rabbits. The intra-and interassay coefficients of variation of PIIINP were 5.3% and 8.5%. The reference interval for serum PIIINP was 1.4-6.9 lg/l (2.5 and 97.5 percentiles) with a 95% confidence interval of 1.0;2.0 and 5.1;7.1 for lower and upper limit, respectively. One patient was excluded due to inadequate serum volume.
HYA was measured at baseline using ELISA provided by Corgenix, Colorado, USA, according to the instructions by the manufacturer. The assay applied microwells coated with a highly specific hyaluronic acid-binding protein (HABP). Upon incubation and washing, an enzymeconjugated version of HABP was added to detect HYA in the samples. The intra-and interassay coefficients of variation of HYA amounted to 3.6% and 6.1%, respectively. The reference interval for HYA was 2.4-77.0 lg/l (2.5 and 97.5 percentiles) with a 95% confidence interval of 2.3;5.3 and 44.0;81.1 for lower and upper limit, respectively.
Anti-CCP antibodies were measured by a secondgeneration ELISA (Immunoscan RA kit, Euro-Diagnostica AB, Malm€ o, Sweden). Serum C-reactive protein (mg/l) and erythrocyte sedimentation rate (ESR; mm/h) were measured according to standard laboratory methods [20] .
Magnetic resonance imaging. Magnetic resonance imaging (MRI) of the non-dominant wrist was performed in eligible patients (n = 130) at baseline and after 1 year (n = 125) [20] . The recordings were obtained before and after intravenous gadolinium contrast injection. MRI measures included evaluation of bone erosions, synovitis and bone marrow oedema according to the OMERACT (Outcome Measures in Rheumatology). MRI scoring system (RAM-RIS) [23] performed by an independent, experienced reader, blinded to the treatment group assignment, clinical and biochemical data.
Statistical analyses. The Mann-Whitney and KruskalWallis tests were applied as appropriate for comparison between groups. Descriptive statistics concerning demographics and disease variables for the groups are presented as medians and interquartile ranges presented within square brackets. Univariate regression analysis was adopted to study correlations between galectin-3, PIIINP or HYA and risk factors, disease activity or imaging variables and was considered significant with P-values ≤ 0.20. Significant variables were subsequently included in multivariate analyses with adjustment for age and gender. A mixed effects regression model, with adjustment for age and gender, was applied for analysis of the galectin-3 pattern over time (baseline, 6, 12 and 48 weeks). Logistic regression analysis was performed to examine the predictive potential of baseline galectin-3 and PIIINP levels upon MRI erosion score at 1-year dichotomized at the median value. In the logistic regression model, we controlled for possible predictors of structural progression (DAS28-CRP, age, gender, anti-CCP and smoking status) and MRI erosion score at baseline.
For normalization of data, we used square root transformation of galectin-3 and a log transformation of PIIINP and HYA. Potential outliers were identified by calculating z-scores. P-values ≤ 0.05 were considered statistically significant. The calculations were performed using STATA version 14.
Results
Among the 160 patients included at baseline, 23 (14%) failed to complete 1 year of follow-up, due to serious adverse events, patient request or other reasons [21] . Baseline characteristics did not differ between completers and dropouts. Upon stratification according to anti-CCP status, positive and negative patients were comparable with regard to age, gender and clinical characteristics, Table 1 .
Based on z-scores, two galectin-3 outliers were identified in both patients and controls. The two patients were consistent outliers throughout the follow-up period indicating a patient-specific source of variation. Five patients were identified as PIIINP outliers and one in the control subset. Similarly, two were found in the HYA control subset and four in the RA sample. Outliers were included in the calculations.
Galectin-3 at baseline and follow-up
In the entire study population, galectin-3 at baseline tended to be higher in patients as compared with healthy control subjects, 4. Galectin-3 did not differ significantly between the treatment arms at baseline or at 12 months follow-up. Therefore, subsequent analyses were done for the entire cohort.
Using a mixed effects regression model, we found that initiation of intensive synovitis suppressive treatment was followed by transiently increasing galectin-3 levels in both treatment arms reaching maximum after 6 weeks, P < 0.001, followed by a gradual descent, P < 0.001, however, without reaching the level of control subjects by 12 months, P < 0.001 (Fig. 1A) . This pattern applied to anti-CCP-positive as well as anti-CCP-negative patients, although the anti-CCP-positive subset had higher serum galectin-3 throughout the follow-up period (Fig. 1B) .
Galectin-3 associations with clinical disease measures
Univariate regression analyses showed that galectin-3 correlated significantly with smoking, anti-CCP status CRP, HAQ and DAS28-CRP, but not with tender and swollen joint counts. In the multiple regression model applied to baseline variables, galectin-3 correlated positively with smoking and anti-CCP positivity, P = 0.04, ( Table 2) . Interaction between smoking and anti-CCP positivity, which were included in the multiple regression model, did not emerge as significant.
Galectin-3 and imaging
Galectin-3 correlated positively with baseline MRI bone marrow oedema score by univariate regression analyses, which included MRI synovitis, erosion and bone marrow oedema scores. However, this correlation did not remain following adjustment for age and gender. Upon follow-up, galectin-3 correlated positively with MRI erosion score at 1 year, also after adjustment for age and gender, P = 0.02. Using logistic regression analysis, baseline galectin-3 did not emerge as a predictor of structural wrist damage at 1 year as assessed by MRI erosion score (OR 1.08, P = 0.89). PIIINP correlated positively with CRP, HAQ, DAS28-CRP, tender and swollen joint counts by univariate regression analysis, while correlations with smoking and anti-CCP status did not emerge as significant. In the multivariate regression analysis, the PIIINP correlation with swollen joint count remained significant, P = 0.006 (Table 2) .
MRI erosion and synovitis scores both emerged as significant in the univariate analysis, but not when applying multivariate analysis. Using logistic regression, baseline PIIINP did not predict structural wrist damage as assessed by MRI erosion score at 1 year (OR 1.96, P = 0.49). Baseline galectin-3 and PIIINP levels did not correlate irrespective of anti-CCP status. There was no significant difference in HYA levels upon stratification according to anti-CCP status, Table 1 . By univariate regression analysis, HYA correlated with CRP, HAQ score, DAS28-CRP, tender and A B Figure 1 Galectin-3 levels (medianinterquartile ranges) at baseline, 6 weeks, 3 and 12 months in the entire RA study population (A) and in anti-CCP subsets (B). Dotted line equals the median galectin-3 in healthy subjects. Using mixed effects regression model, galectin-3 values in the total RA study population were compared to baseline: *P = 0.02 and **P < 0.001 and to controls: #P < 0.01 and ##P ≤ 0.001 applying Mann-Whitney U-test. Table 2 Significant regression coefficients from multivariate analyses of galectin-3, N-terminal propeptide of type III collagen(PIIINP) & hyaluronan.
Characteristic
Square root of Galectin-3 (n = 157) Log PIIINP (n = 159) Log hyaluronan (n = 156) Coeff.
95% CI P-value Coeff. 95% CI P-value Coeff. 95% CI P-value swollen joint counts, MRI synovitis, erosion and bone marrow oedema scores. HYA did not correlate significantly with smoking and anti-CCP status. Upon multivariate regression analysis, HYA correlated significantly with swollen joint count, P = 0.03 and MRI synovitis score, P = 0.004, ( Table 2) . HYA correlated strongly to PIIINP, P < 0.0001), but not to galectin-3, P = 0.31.
Discussion
While increased serum levels of galectin-3 have been reported previously in patients with long-standing RA [9] and in early, undifferentiated arthritis [10] , this is the firstprospective study on galectin-3 comprising patients with newly diagnosed RA before treatment initiation. The study shows that galectin-3 and markers of synovial matrix metabolism (HYA and PIIINP) are elevated in DMARD na€ ıve patients and that galectin-3 remains elevated despite 12-month intensive antirheumatic treatment. Galectin-3 correlated with baseline anti-CCP and smoking as well as MRI erosion score at 1 year but not with core disease activity measures. Conversely, baseline HYA and PIIINP correlated with clinical and imaging indicators of synovitis (swollen joint counts and MRI synovitis score). Neither PIIINP nor HYA differed according to autoantibody or smoking status, and there was no correlation between galectin-3 and HYA or PIIINP. Previously, Ohshima et al. have reported significantly increased galectin-3 levels in patients with long-standing RA as compared with osteoarthritis and healthy controls. Moreover, they found that expression of galectin-3 and its binding protein were increased in the inflamed synovial membrane, particularly at the pannus invasion front suggesting that galectin-3 is implicated in cartilage and bone destruction [9] . In addition, galectin-3 has been shown to induce distinctive pro-inflammatory expression profiles by RA synovial fibroblasts compared with dermal fibroblasts, interleukin-6 (IL-6) and tumour necrosis factor a (TNFa) in particular [12] . Also, joint destruction was significantly less in antigen-induced murine arthritis using galectin-3À/À mice as compared with wild-type animals [11] . Recent data from our group suggest that increased serum level of galectin-3 in early undifferentiated arthritis discriminates well between patients with early, undifferentiated arthritis who will later develop criterial RA versus those who will not [10] . The present findings that galectin-3 is associated with well-established risk factors for erosive progression including anti-CCP and smoking, while not with clinical synovitis measures provide further evidence for a role of galectin-3 in the RA disease pathway, joint destructive processes in particular. The overexpression of galectin-3 and its binding protein at the pannus-cartilage interface in long-standing RA joints adds to the concept of galectin-3 as a mediator of structural joint damage [9] . This notion is further supported by the finding that galectin-3 correlated with erosion score at 1-year follow-up by multivariate regression analysis, although the disease activity assessed by conventional measures was low, and radiographic erosive progression was virtually halted [17, 19] . Furthermore, these findings accord with observations in patients with early, undifferentiated arthritis in whom galectin-3 correlated with wrist bone marrow oedema score [10] . Taken together, these findings may relate to recent research using modern imaging modalities by which it has been shown that residual synovitis is prevalent among RA patients in clinical remission and that erosive progression may still occur in the presence of such smouldering disease activity [4, 24, 25] .
Consecutive recordings of galectin-3 during goaldirected synovitis suppression showed that s-galectin-3 exhibited a transient incremental pattern reaching peak values at 6 weeks, subsequently declining, however, without reaching the healthy control level. This profile was most prominent in seropositive RA (Fig. 1B) . The temporal pattern reported here may reflect that galectin-3 accumulated within the hyaluronan-rich synovial inflammatory infiltrate, for example through binding to carbohydrate ligands on connective tissue constituents [26, 27] is released into the circulation following drug-induced synovitis resolution [14, 16] . Diminished galectin-3 entrapment in the microenvironment of RA joints in conjunction with continuous overexpression of galectin-3 may account for the persistently increased serum level even in clinically quiescent disease. A similar course has been reported following chemotherapy in patients with testicular cancer [28] .
While a positive correlation between PIIINP and galectin-3 has been reported in patients with chronic heart failure [29] , such an association was not observed in the present study. This discrepancy between RA and chronic heart disease may be attributable to differences concerning disease stage or different disease-specific fibrogenetic dynamics.
The study has some limitations. Thus, the tight synovitis control markedly slowed the progression of structural joint damage [17] implying that associations between the unmodified disease course and galectin-3 expression in serum may have been blunted. In addition, at 1 year 14% of the patients had dropped out. However, intention-to-treat and completers-only analysis yielded similar results. A major strength of the study is the large number of patients with newly diagnosed and untreated RA and its prospective design with systematic serial collection of clinical and imaging data, and blood samples.
In conclusion, these findings indicate that in early RA, HYA and PIIINP mainly reflect synovial inflammatory swellings, while galectin-3 is more closely associated with autoimmunity, smoking and joint destructive processes.
